$1.09 Earnings Per Share Expected for Bausch Health Companies Inc. (NYSE:BHC) This Quarter

Analysts expect Bausch Health Companies Inc. (NYSE:BHC) to announce earnings of $1.09 per share for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Bausch Health Companies’ earnings. The lowest EPS estimate is $0.98 and the highest is $1.19. Bausch Health Companies posted earnings of $1.33 per share in the same quarter last year, which would suggest a negative year over year growth rate of 18%. The firm is expected to report its next earnings report on Wednesday, February 23rd.

On average, analysts expect that Bausch Health Companies will report full-year earnings of $4.23 per share for the current financial year, with EPS estimates ranging from $4.11 to $4.32. For the next financial year, analysts expect that the firm will post earnings of $4.73 per share, with EPS estimates ranging from $4.11 to $5.05. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Tuesday, November 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.07. The business had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $2.15 billion. Bausch Health Companies had a negative net margin of 13.85% and a negative return on equity of 2,440.75%.

BHC has been the subject of several recent research reports. BMO Capital Markets reissued a “hold” rating on shares of Bausch Health Companies in a research note on Monday, November 8th. Jefferies Financial Group reissued a “buy” rating on shares of Bausch Health Companies in a research note on Friday, October 1st. Royal Bank of Canada cut their target price on shares of Bausch Health Companies from $41.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, November 3rd. Finally, Barclays cut their target price on shares of Bausch Health Companies from $35.00 to $31.00 and set an “overweight” rating for the company in a research note on Wednesday, August 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $36.22.

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Bausch Health Companies by 1.1% in the 2nd quarter. Vanguard Group Inc. now owns 9,307,234 shares of the company’s stock valued at $272,887,000 after acquiring an additional 96,748 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Bausch Health Companies by 48.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,850,573 shares of the company’s stock worth $230,179,000 after buying an additional 2,553,297 shares in the last quarter. Laurion Capital Management LP lifted its position in Bausch Health Companies by 10.9% in the 3rd quarter. Laurion Capital Management LP now owns 7,536,780 shares of the company’s stock worth $209,899,000 after buying an additional 741,378 shares in the last quarter. Guardian Capital LP lifted its position in Bausch Health Companies by 13.7% in the 2nd quarter. Guardian Capital LP now owns 4,907,407 shares of the company’s stock worth $144,175,000 after buying an additional 591,054 shares in the last quarter. Finally, Miller Value Partners LLC lifted its position in Bausch Health Companies by 2.5% in the 2nd quarter. Miller Value Partners LLC now owns 3,330,390 shares of the company’s stock worth $97,647,000 after buying an additional 79,969 shares in the last quarter. Institutional investors and hedge funds own 75.43% of the company’s stock.

BHC stock traded up $0.08 on Thursday, hitting $26.11. 1,280,183 shares of the company’s stock traded hands, compared to its average volume of 3,088,960. Bausch Health Companies has a 1-year low of $18.49 and a 1-year high of $34.80. The stock has a market cap of $9.37 billion, a price-to-earnings ratio of -7.96, a P/E/G ratio of 1.45 and a beta of 1.56. The stock has a fifty day moving average of $27.66 and a 200-day moving average of $28.69.

About Bausch Health Companies

Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.

Read More: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.